It is unknown whether maintaining lower SF levels in persons with HFE hemochromatosis and diabetes than presently recommended for “maintenance” therapy could maintain or improve insulin secretion and diabetes control or decrease diabetes risk. The gene discussed is INS; the disease is hemochromatosis.